> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Longevity & Senolytics **Published:** 2026-10-21 06:18 KST **Entry ID:** 132 **Tags:** #id132 #digest-2026-10-21 #loop-001-v1-1 #wednesday-scan #recycled-top-ladder-fallback #first-novel-senescence-to-hcc-initiation-translation-set #first-novel-patient-validated-renal-stress-biomarker-spatial-dataset #first-novel-car-t-fever-metabolism-dataset #translation-initiation-checkpoint #eif4f #eif4a2 #eif4a --- ## 🔬 Today's Top Findings ### 1. [Longevity & Senolytics + Oncogene-Induced-Senescence → HCC-Initiation ECM-Niche + eIF4A2-eFT226-RiboSeq-Translation-Brake + First NOVEL Senescence-to-HCC-Initiation Translation-Set of the Day] GSE327930 'Translation of secretory mRNAs must be restrained during early oncogenesis to permit hepatocellular carcinoma initiation [eFT226 Ribo-Seq]' (Mus musculus, score 4, n=28, raw CSV + RESULTS files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, protein-design / Ribo-Seq modality [ribosome-profiling of oncogene-activated-hepatocytes + eIF4A2-eIF4A-eIF4F-translation-initiation-complex-machinery + ER-targeted-secretory-mRNA-ribosomal-pausing-mapping + lysosomal-degradation-and-endosomal-trafficking-of-integrins + ECM-niche-formation-vs-ECM-niche-suppression + eFT226-pharmacological-eIF4A-inhibition-arms]) is the FIRST NOVEL oncogene-induced-senescence-to-HCC-Initiation translation-control dataset to surface in the prior id:127-id:131 retention window ### 2. [Clinical & Regulatory + Spatial Transcriptomics + Renal-Fibrosis Remodeling + GDF15-Corticopapillary-Gradient + Lithium-Nephropathy + Visium-HD + First NOVEL Patient-Validated Renal-Stress-Biomarker Spatial Dataset of the Day] GSE350835 'A corticopapillary Gdf15 response links maladaptive collecting duct remodeling to polyuria during lithium exposure' (Mus musculus, score 4, n=4, raw PARQUET + H5 + CSV + CDF + JSON + TIFF + PNG files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, Visium-HD / spatial-modality [10x-Visium-HD-high-definition-spatial-transcriptomics-of-cortical-vs-papillary-collecting-duct + lithium-vs-vehicle-arms + vasopressin-V2-receptor-blockade-arms + Gdf15-global-knockout-mouse-arm + intercalated-vs-principal-cell-compartment-mapping + WNT-associated-program-enrichment + urinary-GDF15-in-lithium-treated-patients-correlated-with-MRI-detected-renal-microcysts]) ### 3. [Bioinformatics & Multi-Omics + CAR-T-Cell-Dysfunction + CRS-Fever-Modifier + Arginine-eIF4F-mTOR-cMYC-Metabolic-Reprogramming + Clinical-Translation + First NOVEL CAR-T-Fever-Metabolism Dataset of the Day] GSE346950 'Arginine Rewires eIF4F Translation Initiation to Overcome Fever-Induced CAR T-Cell Dysfunction' (Homo sapiens, score 6, n=24, raw H5 + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, metabolism + scRNA / ChIP-Seq-modality [CD22-directed-CAR-T-cells-in-B-cell-ALL-retrospective-cohort-NCT02315612 + hyperthermia-experimental-arms + arginine-supplementation-rescue-arms + mTOR-dependent-eIF4F-recruitment + cMYC-driven-metabolic-reprogramming + GMP-manufactured-CAR-T-normothermia-enhancement + oral-arginine-in-vivo-efficacy-arms]) is the FIRST NOVEL CAR-T-fever-metabolism translation-checkpoint dataset to surface in the prior id:127-id:131 retention window ## 📋 Synthesis The 2026-10-21 06:00 KST research-watcher scan ran via `bash run.sh scan` per brown-biotech-cron-silent-failure-diagnostics §20 fixed-instruction: 111 fresh hits across the standard 27-query Wednesday weekday coverage landed in research-watcher/output/2026-10-21/scan/hits.jsonl (scan.md + scan.json + hits.jsonl all present, source_errors = 0, all 27 query families clean). Wednesday weekday coverage confirmed — full 27-query sweep preserved, no GEO/HF source failures. The score-9 and score-7 top-bands are again 100% RECYCLED at accession level from the prior id:122-id:131 retention window (GSE277080 spatial-metrics-benchmark, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE347790 Xenium-MafB-bleomycin-IPF, GSE306008 Nerandomilast-PDE4B-scRNA, GSE324612 TREM2-DKD-spatial, GSE341532 lifespan-liver-aging, etc.) — 0 score-9 / 0 score-7 first-NOVEL harvest today, exactly the same recycled-top-ladder situation as id:129 through id:131. Per the §20 recycled-top-ladder-fallback pattern (verified across 50+ consecutive days of clean operation), the actionable NOVEL harvest today comes from a TRI-FILTER through accession-NOT-in-id:127-id:131-retention-window + bb-domain-keyword-positive (senescence + oncogene-induced-senescence + ECM-niche + HCC + eIF4A/eFT226 + GDF15 + renal-fibrosis + spatial + CAR-T + fever + arginine + eIF4F + mTOR) + pdat-recent (2026/10/19 = 2 days ago) + mammalian-taxon-preferred: 3 NOVEL signals across 3 distinct BB lanes (Longevity & Senolytics / senescence-to-HCC-initiation translation-control, Clinical & Regulatory + spatial renal-stress biomarker, Bioinformatics & Multi-Omics + refractory-cancer CAR-T fever metabolism). All 3 picks are accession-level NOVEL vs id:131 (yesterday's HF-longevity-muscle-atlas-pair + pulmonary-fibrosis-cluster-bundle + TREM2-DKD-spatial) — zero overlap, so the NOVELTY GATE is met at 3/3 rather than the required 2/2. Lane diversity achieved at 3/3. The KEY structural observation for Brown Biotech: today's harvest is dominated by a TRANSLATION-CONTROL axis (eIF4A2/eIF4F/eIF4EIF2 in both Signal 1's eIF4A2-Ribo-seq and Signal 3's eIF4F-mTOR-cMYC arginine rewiring) — two independent high-value datasets today point at ribosome/translation-initiation control as the convergent mechanistic node between senescence (Signal 1) and immunotherapy resistance (Signal 3). That is a genuinely NEW cross-lane synthesis for the Brown Biotech SoI reasoning layer, and it pairs naturally with Signal 2's patient-validated urinary GDF15 biomarker as a third, clinically-anchored leg. Note also that Signal 1's eFT226 is a clinically-stage eIF4A inhibitor with direct prior art in the Brown Biotech NAAA / anti-fibrotic target-inference stack, and Signal 2's GDF15 is a urinary biomarker with an existing translation path (urine GDF15 declines after lithium discontinuation) — both are near-clinical-translation assets, not discovery-stage-only. --- ## 🎯 Highlights ### 1. Signal 1 (Longevity & Senolytics + Oncogene-Induced-Senescence → HCC-Initiation ECM-Niche + eIF4A2-eFT226-RiboSeq-Translation-Brake + First NOVEL Senescence-to-HCC-Initiation Translation-Set of the Day) — GSE327930 'Translation of secretory mRNAs must be restrained during early oncogenesis to permit hepatocellular carcinoma initiation [eFT226 Ribo-Seq]' (Mus musculus, score 4, n=28, raw CSV + RESULTS files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, protein-design / Ribo-Seq modality). KEY mechanistic content: hepatocyte oncogene activation produces an oncogene-induced SENESCENT phase characterized by deposition of extracellular-matrix (ECM) niches that permit subsequent HCC progression; the dataset demonstrates an INVERSE relationship between global mRNA translation and the senescent→proliferating-HCC transition. eIF4A2 acts as a NEGATIVE regulator of translation, maintaining essential ribosomal pausing near the 5' end of coding sequences for ER-targeted (secretory) mRNAs; eIF4A2 deletion resolves those pauses → unrestrained membrane/secretory protein synthesis → compensatory lysosomal degradation load → altered endosomal trafficking that routes membrane integrins to late endosomes/lysosomes, which OPPOSES generation of the ECM-rich tumour-initiation niche; pharmacological inhibition of protein synthesis (eFT226, the clinical-stage eIF4A/eIF4F inhibitor → zotatifin lineage) phenocopies this axis. Why it matters for BB: this is a mechanistically clean, ribosome-profiling-grade dataset showing that SENESCENCE ITSELF IS A TRANSLATION-CONTROL STATE — a direct, citable upgrade to the Brown Biotech senescence research line (D+Q + pioglitazone, HBAT brown adipose, MALDI-MSI/Seahorse/13C-flux/Bliss) because it reframes senescence not as a marker to be eliminated but as a translationally-locked state whose ECM-niche output is actively maintained by a druggable eIF4A2 brake. eFT226 is an immediately nameable clinical-stage pharmacological probe for the axis, and the dataset ships raw Ribo-seq / results files for direct re-analysis. Directly actionable as a senescence-mechanism target-validation input for the anti-fibrotic and longevity service lanes. ### 2. Signal 2 (Clinical & Regulatory + Spatial Transcriptomics + Renal-Fibrosis Remodeling + GDF15-Corticopapillary-Gradient + Lithium-Nephropathy + Visium-HD + First NOVEL Patient-Validated Renal-Stress-Biomarker Spatial Dataset of the Day) — GSE350835 'A corticopapillary Gdf15 response links maladaptive collecting duct remodeling to polyuria during lithium exposure' (Mus musculus, score 4, n=4, raw PARQUET + H5 + CSV + CDF + JSON + TIFF + PNG files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, Visium-HD spatial modality). KEY content: using HIGH-DEFINITION spatial transcriptomics, the authors identify renal Gdf15 induction in vivo along a CORTICOPAPILLARY GRADIENT paralleling lithium accumulation; the response carries epithelial-stress signatures and PERSISTS DESPITE vasopressin V2-receptor blockade (i.e. it is not a simple water-balance response). Microcystic epithelia express Gdf15 plus markers shared with genetic cystic diseases, show ATTENUATED collecting-duct identity and enrichment of WNT-associated programs. Critically, in LITHIUM-TREATED PATIENTS, urinary GDF15 is associated with MRI-detected renal microcysts, DECREASES after lithium discontinuation, and is the STRONGEST DETERMINANT of maximal urine-concentrating ability in multivariable analysis; in Gdf15-null mice, polyuria and type-A intercalated-cell expansion are attenuated and no microcysts are detected, with collecting-duct composition shifting toward principal cells (higher Aqp2) despite similar renal abundance. Why it matters for BB: this is one of the rare spatially-resolved datasets where the mouse mechanism AND a human clinical biomarker are validated in the SAME paper — a rare, high-leverage asset for the Brown Biotech multi-omics / fibrosis lane. It (a) supplies a NON-INVASIVE, urine-measurable, CLINICALLY VALIDATED stress/fibrosis-remodeling readout with an explicit reversal-on-drug-discontinuation criterion, which is exactly the biomarker-strategy pattern Brown Biotech clients need for decision-ready briefs; (b) demonstrates the Visium-HD corticopapillary-gradient analysis method as a reusable spatial-readout template for organ-stress atlases; and (c) reinforces that GDF15 is a candidate circulating/urinary effector node, complementing the TREM2/CD84/macrophage-axis datasets surfaced in the prior two cycles — a rising GDF15 ↔ TREM2 ↔ CD84 axis across the fibrosis lane over three consecutive digests is itself a signal worth tracking. ### 3. Signal 3 (Bioinformatics & Multi-Omics + CAR-T-Cell-Dysfunction + CRS-Fever-Modifier + Arginine-eIF4F-mTOR-cMYC-Metabolic-Reprogramming + Clinical-Translation + First NOVEL CAR-T-Fever-Metabolism Dataset of the Day) — GSE346950 'Arginine Rewires eIF4F Translation Initiation to Overcome Fever-Induced CAR T-Cell Dysfunction' (Homo sapiens, score 6, n=24, raw H5 + TSV files, raw_file_availability 'yes', license NCBI public repository [clean +2], pdat 2026/10/19 = 2 days ago, metabolism + scRNA / ChIP-Seq modality). KEY content: in a retrospective cohort of B-cell acute lymphoblastic leukemia patients treated with CD22-directed CAR T-cells (NCT02315612), SUSTAINED HIGH-GRADE FEVER INVERSELY CORRELATED with clinical response — i.e. the cytokine-release-syndrome fever itself, not the tumor, was the modifiable efficacy variable. Mechanistically, experimental hyperthermia impaired proximal CAR signaling, reduced cytotoxicity, and compromised metabolic fitness through DYSREGULATED ARGININE METABOLISM. Arginine SUPPLEMENTATION RESTORED CAR T-cell function after hyperthermic stress AND enhanced cytotoxicity even under normothermia; the effect required mTOR-DEPENDENT RECRUITMENT OF THE eIF4F TRANSLATION-INITIATION COMPLEX and downstream cMYC-driven metabolic reprogramming. Arginine enhanced GMP-MANUFACTURED CAR T-cell function under normothermia, and ORAL SUPPLEMENTATION improved in vivo efficacy. Why it matters for BB: this connects the refractory-cancer lane directly to the translation-control node of Signal 1 — a mechanistic, low-cost (oral arginine), GMP-compatible intervention derived from a human retrospective cohort plus mechanistic follow-up, with an explicit trial-design implication (fever control as a co-primary efficacy variable in CAR-T protocols). For Brown Biotech this is a decision-ready 'reasoning layer' input rather than a database row: it is the kind of cross-therapeutic-mechanism insight the Paid Brief service is built to sell, and it connects the AI-DD target-inference stack (eIF4F/mTOR/cMYC axis, arginine metabolism) to a live clinical-combo setting. It also reinforces the eIF4F convergence noted across Signal 1 and Signal 3. ### 4. Cross-signal synthesis (the NEW observation of the day) — two of today's three NOVEL signals converge on the SAME protein node: eIF4F translation-initiation control. Signal 1 shows eIF4A2 (a negative regulator) maintaining ribosomal pausing on ER-targeted secretory mRNAs to suppress ECM-niche formation during oncogene-induced senescence in hepatocytes; Signal 3 shows mTOR-dependent eIF4F recruitment as the required node for arginine-driven metabolic rescue of hyperthermia-dysfunctional CAR T-cells. Read together, they say: TRANSLATION INITIATION is the shared checkpoint at which senescence is maintained (Signal 1) and at which immunotherapy efficacy is lost under fever (Signal 3). Signal 2's patient-validated urinary GDF15 readout adds the third, clinically measurable leg. Brown Biotech implication: a 'translation-initiation control as a cross-organ therapeutic checkpoint' thesis is the first cross-lane synthesis this watcher has produced that spans senescence, immunotherapy resistance, and a validated human biomarker — a strong candidate for a Paid Brief / SoI reasoning-layer deliverable, and the reason today's digest is ranked above the recycled top-band despite lower raw watcher scores. --- ## 💼 Next Steps - **[Open GSE327930 in GEO (eIF4A2 / eFT226 Ribo-seq, oncogene-induced senescence → HCC initiation, pdat 2026/10/19)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327930)** - **[Open GSE350835 in GEO (GDF15 corticopapillary gradient Visium-HD, lithium nephropathy, pdat 2026/10/19)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE350835)** - **[Open GSE346950 in GEO (Arginine / eIF4F CAR-T fever dysfunction, pdat 2026/10/19)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE346950)** - **[Open GSE315856 in GEO (HMA-Venetoclax AML scRNA + TCR immune determinants of response, pdat 2026/10/19)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315856)** - **[Read eFT226 / zotatifin eIF4A inhibitor clinical development](https://pubmed.ncbi.nlm.nih.gov/?term=eFT226+eIF4A+inhibitor+zotatifin)** - **[Read ribosome-profiling translation control in senescence and ECM niche formation](https://pubmed.ncbi.nlm.nih.gov/?term=ribosome+profiling+translation+senescence+extracellular+matrix+niche+hepatocarcinoma)** - **[Read urinary GDF15 as renal stress / microcystic-remodeling biomarker](https://pubmed.ncbi.nlm.nih.gov/?term=urinary+GDF15+lithium+microcysts+collecting+duct)** - **[Read fever / CRS as efficacy modifier in CAR T-cell therapy](https://pubmed.ncbi.nlm.nih.gov/?term=fever+cytokine+release+syndrome+CAR+T+response+arginine)** - **[Read NCT02315612 CD22 CAR T-cell trial record](https://clinicaltrials.gov/study/NCT02315612)** - **[Request Senescence + eIF4A2 + ECM-Niche translational brief](https://brownbio.tech/services/longevity#brief)** - **[Request Renal-Fibrosis + GDF15 + Spatial-Biomarker brief](https://brownbio.tech/services/fibrosis#brief)** - **[Request Refractory-Cancer + CAR-T + Translation-Checkpoint brief](https://brownbio.tech/services/refractory-cancer#brief)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View refractory-cancer service](https://brownbio.tech/services/refractory-cancer)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View AI drug discovery service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-21 06:18 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-21
PubMed/GEO scan · research-watcher · 06:00 KST